Adverum Biotechnologies, Inc. (ADVM)
| Market Cap | 232.11M |
| Revenue (ttm) | 7.50M |
| Net Income (ttm) | -123.04M |
| Shares Out | 97.75M |
| EPS (ttm) | -1.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $2.38 |
| Previous Close | $2.37 |
| Change ($) | 0.01 |
| Change (%) | 0.42% |
| Day's Open | 2.37 |
| Day's Range | 2.33 - 2.53 |
| Day's Volume | 2,418,892 |
| 52-Week Range | 2.26 - 19.25 |
-- Based on latest analyses, company is revising ADVM-022 development plan to focus on wet AMD and low doses (2 x 10^11 vg/eye and lower); no longer planning development for DME -- -- Company to host ...
Adverum Biotechnologies (ADVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
-- Christopher J. DeRespino appointed acting CFO -- -- Peter Soparkar appointed COO --
There are some investors who invest in U.S.-listed stocks that are trading below their liquidation values because they believe they can gain from these allocations after the market has reappraised the s...
The uncertainty over the biotech's lead clinical asset weighed on its shares last month.
Investors need to pay close attention to Adverum (ADVM) stock based on the movements in the options market lately.
Adverum Biotechnologies (ADVM) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...
REDWOOD CITY, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, toda...
HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...
NEW YORK, May 11, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ: ADVM). Such investors are advi...
HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...
REDWOOD CITY, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies Inc. (“Adverum”) (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare dis...
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 23.68% and 1530.44%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
REDWOOD CITY, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, toda...
Akebia Therapeutics Inc ( AKBA , Financial), Adverum Biotechnologies Inc ( ADVM , Financial) have performed so poorly over the prior 52 weeks through May 5, with the share prices losing more than 59%, t...
HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...
HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...
Adverum Biotechnologies Inc (NASDAQ: ADVM) has announced new long-term data from the OPTIC Phase 1 trial of ADVM-022 single intravitreal (IVT) injection gene therapy in patients with neovascular or wet ...
-- Long-term durability and maintained efficacy; sustained robust aflibercept protein expression observed -- -- 60% of patients injection free beyond 1 year following 2 x 10^11 single dose --
Adverum Biotechnologies (NASDAQ: ADVM) shares are trading lower after the company announced a Suspected Unexpected Serious Adverse Reaction of hypotony in its INFINITY clinical trial evaluating ADVM-022...
HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...
Investors are running for the hills following the company's latest clinical update.
REDWOOD CITY, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant d...
HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...
HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...
Urges Stockholders to Vote the WHITE Proxy Card “FOR” ALL of Adverum's Three Highly Qualified, Diverse and Independent Directors: Dawn Svoronos, Reed V. Tuckson, M.D. and Thomas Woiwode, Ph.D.
Sonic's Nominees Lack Experience and Qualifications to Advance Adverum's Commercialization Progress or Deliver Global Access to Vision-Saving Gene Therapy
HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...
-- Adverum to host webcast with key opinion leaders on Sunday, May 2, 2021 at 7:00 AM PT -- REDWOOD CITY, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a cli...
HONOLULU, April 8, 2021 /PRNewswire/ -- The Sonic Fund II, L.P. ("Sonic"), which beneficially owns approximately 6.7% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the...
-- Anand Reddi appointed vice president, patient advocacy, access, and digital innovation -- -- Bill Tan, PharmD, appointed vice president, clinical operations program lead --
REDWOOD CITY, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, to...
Responds to Intent to Nominate Directors from Sonic Fund
Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of -21.88% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the s...
-- BLA submission targeted in 2024 -- -- Alignment on clinical development and CMC requirements from recent interactions with FDA --
Key Opinion Leader Arshad M. Khanani, M.D., M.A., director of clinical research, Sierra Eye Associates, and OPTIC and INFINITY trial investigator will participate on this call Key Opinion Leader Arshad ...
REDWOOD CITY, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, tod...
REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, tod...
REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, tod...
Adverum Biosciences stock, a clinical stage gene therapy company focused on serious ocular and rare diseases, has rallied by a solid 18% over the last 5 trading days, after the company disclosed in regu...
Adverum Biotechnologies (ADVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.
-- 174,000-square-foot commercial GMP facility in Durham, NC for the manufacturing of ADVM-022, an intravitreal gene therapy in development for wet AMD and DME -- -- Multiple production suites with tota...
REDWOOD CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, tod...
-- Maintained efficacy and greatly reduced anti-VEGF treatment burden after a single IVT injection of ADVM-022 -- -- R obust preliminary aqueous a nti-VEGF protein expression observed at 18 months in C...
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 11.43% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the s...
-- Dr. Carl Regillo to present OPTIC data a t the R etina S ubspecialty D ay on Friday, November 13, 2020 at 2:15 pm PT -- -- Company to host webcast with key opinion leaders on Saturday , November 14 ...
About ADVM
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was ... [Read more...]
| Industry Biotechnology | IPO Date Jul 31, 2014 |
| CEO Leone Patterson | Employees 167 |
| Stock Exchange NASDAQ | Ticker Symbol ADVM |
Analyst Forecasts
According to 11 analysts, the average rating for ADVM stock is "Buy." The 12-month stock price forecast is 7.88, which is an increase of 231.09% from the latest price.